n o i rd 3 Con l’adesione del Presidente della Repubblica t i d E Scientific Programme orkshop Innovation in HIV and Viral Hepatitis Beyond viral undetectability: new frontiers and strategies Scientific Coordinators Antonella d’Arminio Monforte (Milan, I) Carlo Federico Perno (Rome, I) Massimo Puoti (Milan, I) Milan, Italy Palazzo delle Stelline January 26-27, 2015 Depositato presso AIFA in data 08/05/14 orkshop Innovation in HIV and Viral Hepatitis Beyond viral undetectability: new frontiers and strategies Endorsements Ministero della Salute Istituto Superiore di Sanità Agenzia Italiana del Farmaco Regione Lombardia Università degli Studi, Milan Dipartimento di Scienze della Salute, Università degli Studi, Milan Università degli Studi Tor Vergata, Rome Azienda Ospedaliera San Paolo - Polo Universitario, Milan Azienda Ospedaliera Niguarda Ca’ Granda, Milan Fondazione Policlinico Tor Vergata, Rome SIMIT, Società Italiana Malattie Infettive e Tropicali SIVIM, Società Italiana di Virologia Medica AISF, Associazione Italiana per lo Studio del Fegato AMCLI, Associazione Microbiologi Clinici Italiani Fondazione AVIRALIA Fondazione ICONA ANLAIDS, Associazione Nazionale per la lotta contro l’AIDS EpaC Associazione Onlus LILA, Lega Italiana per la lotta contro l’AIDS Associazione NADIR NPS Italia, Network Persone Sieropositive Honorary President Mauro Moroni Professor Emeritus, University of Milan I Scientific Coordinators Antonella d’Arminio Monforte San Paolo Hospital, University of Milan I Carlo Federico Perno University of Tor Vergata, Rome I Massimo Puoti Niguarda Ca’ Granda Hospital, Milan I Scientific Secretariat Francesca Ceccherini-Silberstein University of Tor Vergata, Rome I Giulia Marchetti San Paolo Hospital, University of Milan I Roberto Rossotti Niguarda Ca’ Granda Hospital, Milan I Faculty Alessio Michele Aghemo Foundation IRCCS Maggiore Hospital, University of Milan I Massimo Galli Luigi Sacco Hospital, University of Milan I Savino Bruno Fatebenefratelli Hospital, University Milan Bicocca, Milan I Giulia Marchetti San Paolo Hospital, University of Milan I Alessia Maria Giorgini San Paolo Hospital, University of Adriana Ammassari IRCCS - INMI Lazzaro Spallanzani, Milan I Rome I Enrico Girardi IRCCS - INMI Lazzaro Spallanzani, Rome I Massimo Andreoni University of Tor Vergata, Rome I Andrea Gori San Gerardo Hospital, Monza I Gioacchino Angarano University Hospital of Bari I Peter Hunt University of California, San Francisco USA Mario Angelico University of Tor Vergata, Rome I Paul Klenerman Nuffield Department of Medicine, Andrea Antinori IRCCS - INMI Lazzaro Spallanzani, University of Oxford UK Rome I Adriano Lazzarin University Vita-Salute San Raffaele, Guido Antonelli University Hospital Umberto I and Milan I Sapienza University, Rome I Massimo Levrero Sapienza University, Rome I Stefano Bonora University of Turin I Miriam Lichtner Sapienza University of Rome, Polo Raffaele Bruno University of Pavia I Pontino, Latina I Andrea Calcagno University of Turin I Giampiero Carosi Professor Emeritus, University of Brescia I Fabio Marra University of Florence I Claudio Maria Mastroianni Sapienza University of Rome, Polo Pontino, Latina I Gabriele Missale University Hospital of Parma I Antonella Castagna San Raffaele Scientific Institute, Milan I Mauro Moroni Professor Emeritus, University of Milan I Dario Cattaneo Luigi Sacco Hospital, University of Milan I Cristina Mussini University Hospital of Modena and Reggio Emilia, Modena I Francesca Ceccherini-Silberstein University of Tor Vergata, Rome I Carlo Federico Perno University of Tor Vergata, Rome I Antonella Cingolani Catholic University, Rome I Massimo Clementi University Vita-Salute San Raffaele, Milan I Massimo Colombo Foundation IRCCS Maggiore Hospital, University of Milan I Andrea Cossarizza University Hospital of Modena and Reggio Emilia, Modena I Antonella d’Arminio Monforte San Paolo Hospital, University of Milan I Gabriella d’Ettorre University Hospital Umberto I, Rome I Massimo Pinzani Institute for Liver and Digestive Health, University College London, Royal Free Hospital, London UK Teresa Maria Pollicino G. Martino University Hospital, Messina I Massimo Puoti Niguarda Ca’ Granda Hospital, Milan I Giovanni Raimondo University Hospital of Messina I Giuliano Rizzardini Luigi Sacco Hospital, University of Milan I Stefano Rusconi Luigi Sacco Hospital, University of Milan I Andrea De Luca Siena University Hospital, Siena I Teresa Antonia Santantonio University Hospital of Andrea De Maria University of Genoa, IRCCS AOU San Foggia I Martino - IST Genoa I Annalisa Saracino University Hospital of Bari I Giovanni Di Perri University of Turin I Guido Silvestri Emory University School of Medicine, Daniel C. Douek Vaccine Research Center, National Yerkes National Primate Research Center, Atlanta USA Institute of Allergy and Infectious Diseases, National Mario Strazzabosco University Milan Bicocca, Milan I Institutes of Health, Bethesda USA Valentina Svicher University of Tor Vergata, Rome I Carlo Ferrari University Hospital of Parma I Gloria Taliani Sapienza University, Rome I Courtney V. Fletcher University of Nebraska Medical Center, College of Pharmacy, Omaha USA Camilla Tincati San Paolo Hospital, University of Milan I Charles W. Flexner Johns Hopkins University, Baltimore USA Erica Villa University of Modena and Reggio Emilia, Modena I Giovanni Battista Gaeta Second University of Naples I Massimo Zuin San Paolo Hospital, University of Milan I 5 orkshop Innovation in HIV and Viral Hepatitis Beyond viral undetectability: new frontiers and strategies Scientific Programme January 26, 2015 11.00-11.10 Welcome addresses 11.10-11.20 Rationale and presentation of the Workshop M. Moroni A. d’Arminio Monforte, C.F. Perno, M. Puoti 11.20-12.20 OPENING LECTURES Conveners: G. Antonelli, A. De Maria 11.20-11.40 Mechanisms of protection from SIV/HIV disease progression 11.40-12.00 Impact of HIV & HCV viral burden at population level: what strategies to contain epidemics? G. Silvestri E. Girardi M. Clementi, G.B. Gaeta, A. Lazzarin 12.00-12.20 Discussion Mechanisms of viral persistence: what role for the virus and what for the host? 12.20-13.40 SESSION 1 Conveners: G. Di Perri, M. Strazzabosco 12.20-12.40 12.40-13.00 13.00-13.20 13.20-13.40 HIV - What obstacles for the cure? The host vs the virus HCV - Why the virus becomes chronic? HBV - Why the virus becomes chronic? Discussion D.C. Douek P. Klenerman T.M. Pollicino A.M. Aghemo, A. Cossarizza 13.40-14.30 Lunch and poster discussion 14.30-15.15 SESSION 2 Oral communications Conveners: S. Bruno, C.M. Mastroianni based on selected abstracts PNPLA3 variant is an independent predictor of severe steatosis in patients with chronic hepatitis C and HIV infection C. Sagnelli1, M. Merli2, C. Uberti-Foppa2, N. Coppola3, H. Hasson2,1, G. Cirillo4, A. Gradone4, S. Salpietro2, C. Minichini3, E. Miraglia Del Giudice4, A. Lazzarin2, E. Sagnelli3 1 Department Experimental Medicine and Surgery "F. Magrassi e A. Lanzara", Second University of Naples, Naples, Italy; 2Department of Infectious Diseases, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy; 3Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy; 4Department of Pediatrics, Second University of Naples, Naples, Italy HIV-1 Impairs CD62L Expression and Function L. Vassena, E. Giuliani, M. Doria Bambino Gesù Children's Hospital, IRCCS, Rome, Italy Clonal Expansion of Infected Cells as a Mechanism of HIV Persistence F. Simonetti1,2, S. Hill2, M. Gouzoulis2, W. Shao3, X. Wu3, M. Kearney3, S. Hughes3, J. Coffin3, J. Mellors4, F. Maldarelli2 1 University of Milan, Milan, Italy; 2National Cancer Institute, Frederick, MD, USA; 3Leidos Biomedical Research, Frederick, MD, USA; 4Tufts University, Boston, MA, USA; 5University of Pittsburg, PA, USA 6 January 26, 2015 HCV NS3 Quasispecies in Liver and Plasma and Dynamics of Telaprevir-resistant Variants Assessed by UDPS in Breakthrough Patients: a Case Study B. Bartolini, M. Selleri, A.R. Garbuglia, E. Giombini, G. D’Offizi, M.R. Capobianchi National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy Immune cytotoxic response selects a growing number of defective viral variants during the natural history of HBV infection, some of which are not detectable in the periphery: possible implications for the pathogenesis and for the clinical management of patients with chronic hepatitis B C. Minosse1, M. Selleri1, A. Baiocchini2, E. Giombini1, S. Coen1, P. Zaccaro1, G. Rozera1, D. Vincenti1, U. Visco Comandini3, R. Lionetti3, M. Montalbano3, G. D'Offizi3, M.R. Capobianchi1, S. Menzo4 1 Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy; 2Laboratoy of Pathology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy; 31st Clinical Division, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy; 4Laboratory of Virology, Università Politecnica delle Marche, Ancona, Italy A potential role of dendritic cell and monocytes assessment in predicting response to therapy in HCV infected subjects S. Vita1, M. Lichtner2, S. Savinelli1, C. Mascia1, T. Tieghi2, R. Marocco2, P. Zuccalà1, F. Schiavone1, F. Mengoni1, V. Vullo1, C.M. Mastroianni2 1 Public Health and Infectious Diseases, Sapienza University, Rome, Italy; 2Infectious Diseases Unit, Sapienza University, Polo Pontino, Latina, Italy 15.15-16.20 SESSION 3 Beyond viral undetectability in plasma: which markers of therapy outcome Conveners: M. Colombo, G. Rizzardini 15.15-15.30 HIV - Case presentation and open questions 15.15-15.25 HIV case presentation 15.25-15.30 Open questions G. d’Ettorre P. Hunt 15.30-15.45 HCV - Case presentation and open questions 15.30-15.40 HCV case presentation 15.40-15.45 Open questions F. Ceccherini-Silberstein M. Zuin 15.45-16.00 HBV - Case presentation and open questions 15.45-15.55 HBV case presentation 15.55-16.00 Open questions V. Svicher G. Raimondo 16.00-16.20 Discussion A. Gori, C. Mussini 16.20-16.35 Coffee break 16.35-18.25 SESSION 4 Eradication and Conveners: A. Antinori, G. Carosi 16.35-16.45 16.45-17.05 17.05-17.25 17.25-17.45 17.45-18.05 18.05-18.25 functional cure: pharmacology Framing the problem Insight the HIV reservoirs Insight the HCV-related cirrhosis Long-Acting injectable ARVs: dream or reality? Insight the HBV reservoirs Discussion 7 A. Antinori C.V. Fletcher F. Marra C.W. Flexner M. Levrero A. Calcagno, D. Cattaneo orkshop Innovation in HIV and Viral Hepatitis Beyond viral undetectability: new frontiers and strategies Scientific Programme January 27, 2015 09.00-09.30 LECTURE Conveners: G. Angarano, M. Galli 09.00-09.20 CCR5 and modulation of fibrosis progression in HIV/HCV coinfection 09.20-09.30 Discussion 09.30-10.30 SESSION 5 Difficult to treat Conveners: M. Andreoni, M. Angelico R. Bruno patients: what therapeutic strategy? 09.30-09.40 Framing the problem M. Andreoni 09.40-09.55 High HIV viremia: case presentation and open questions 09.40-09.50 Does more aggressive anti HIV therapy work? 09.50-09.55 Open questions C. Tincati A. De Luca 09.55-10.10 HCV-related cirrhosis: case presentation and open questions 09.55-10.05 What treatment options for low HCV decay? 10.05-10.10 Open questions 10.10-10.30 Discussion A.M. Giorgini M. Pinzani G. Missale, S. Rusconi 10.30-10.45 Coffee break 10.45-11.30 SESSION 6 Oral communications Conveners: C. Ferrari, A. Saracino based on selected abstracts α + Inherent transcriptional signatures of NK cells are associated with response to IFNα ribavirin therapy in patients with Hepatitis C Virus M.L. Ascierto1,2, F. Bozzano1,3, D. Bedognetti4, F. Marras5, C. Schechterly6, A. Picciotto7, S. Marenco7, Y. Zhao8, V. De Giorgi6, M. Sommariva6, L. Moretta5, E. Wang4, H.J. Alter6, F.M. Marincola4, A. De Maria1,3,7 1 Department of Health Sciences, University of Genoa, Italy; 2Department of Oncology, Johns Hopkins University, Baltimore, MD, USA; 3Department of Experimental Medicine, University of Genoa, Italy; 4Sidra Medical and Research Centre, Doha, Qatar; 5Istituto Giannina Gaslini, Genova, Italy; 6Department of Transfusion Medicine, Clinical Center and Center of Human Immunology, National Institutes of Health, Bethesda, MD, USA; 7IRCCS Az. Osp. Univ. San Martino-IST Istituto Nazionale Ricerca sul Cancro, Genova, Italy; 8Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Sofosbuvir-based all-oral treatment for elderly Chronic Hepatitis C patients: a costeffectiveness analysis A. Ciaccio1, P.A. Cortesi2, G. Bellelli3, M. Rota4, M. Rota1, S. Okolicsanyi1, L.G. Mantovani2, G. Annoni3, M. Strazzabosco1,5 1 Department of Surgery and Translational Medicine; 2Research Centre on Public Health (CESP); 3Department of Health Sciences, Geriatric Medicine; 4Department of Health Sciences, Centre of Biostatistics for Clinical Epidemiology, University of Milan-Bicocca, Milan, Italy; 5Liver Center & Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA 8 January 27, 2015 Peripheral and CSF immune-activation and inflammation are associated with elevated CSF HIV–RNA in antiretroviral naïve HIV-infected individuals E. Merlini1, F. Bai1, F. Iannuzzi1, M. Trunfio1, A. Calcagno2, S. Bonora2, E.S. Cannizzo1, M. Basilissi1, G. Marchetti1 and A. d’Arminio Monforte1 1 University of Milan, Dept of Health Sciences, Italy; 2University of Turin, Italy Final results of Telaprevir-based therapy in HCV/HIV patients with severe fibrosis A. Gori1, M. Doroana2, O. Chernova3, J. Rockstroh4, D. Banhegyi5, C. Bergin6, G. Verucchi7, R. DeMasi8, B. Hadacek9, M. Nelson10 1 Division of Infectious Diseases, San Gerardo Hospital, Monza, Italy; 2Servico de Doencas Infecciosas, Hospital de Santa Maria, Lisbon, Portugal; 3State Healthcare Institution, Tolyatti, Russian Federation; 4Department of Internal Medicine, University Hospital Bonn, Bonn, Germany; 5Szent Laszlo Hospital, Budapest, Hungary; 6Department of Genitourinary Medicine and Infectious Diseases, St James Hospital, Dublin, Ireland; 7Division of Infectious Diseases, University of Bologna, Bologna, Italy; 8Janssen Research and Development LLC, Titusville, NJ, USA; 9Janssen Pharmaceuticals, Paris, France; 10Chelsea and Westminster Hospital, London, United Kingdom Slow HCV kinetics following Sofosbuvir + Ribavirin administration in real-life setting of liver transplant recipients with severe recurrent hepatitis C V. Cento1, M.F. Donato2, I. Lenci3, M. Rendina4, V.C. Di Maio1, M. Milana3, S. Monico2, M. Aragri1, R. Alfieri5, A. Abedrabbo3, D. Sforza6, M. Manuelli6, L. Mameli7, M.C. Sorbo1, R. Canu8, M.L. Ponti8, C. Chialà4, F. Malinverno2, S. Marenco9, L. Milanesi5, A. Picciotto9, G. Rossi2, A. Di Leo4, G. Tisone6, F. Zamboni7, R. Ganga8, M. Colombo2, C.F. Perno1,10, M. Angelico3, F. Ceccherini-Silberstein1 1 Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy; 2Gastroenterology and Liver Transplant Units, Fondazione IRCCS Cà Granda Maggiore Hospital Policlinico and University of Milan, Milan, Italy; 3Hepatology Unit, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy; 4Gastroenterology and Digestive Endoscopy, University Hospital, Policlinico Bari, Bari, Italy; 5Institute for Biomedical Technologies, National Research Council, Segrate (MI), Italy; 6Liver Transplant Centre, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy; 7Liver Transplant Centre, Azienda Ospedaliera G Brotzu, Cagliari, Italy; 8Internal Medicine Unit, Azienda Ospedaliera G Brotzu, Cagliari, Italy; 9Unit of Diagnosis and Therapy of Liver Diseases, “San Martino” Hospital, Genoa, Italy; 10Virology Unit, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy 11.30-13.20 SESSION 7 Infection and gender: Conveners: A. Cingolani, T.A. Santantonio 11.30-11.40 11.40-12.00 12.00-12.20 12.20-12.40 12.40-13.00 13.00-13.20 any differences? Framing the problem Antiviral drug toxicity and pharmacokinetics HIV: which biological differences according to gender? HCV: natural history of chronic liver disease The setting of HIV/HCV coinfection Discussion 13.20-13.30 SESSION 8 Closing remarks Conveners: A. d’Arminio Monforte, C.F. Perno, M. Puoti 9 A. Ammassari S. Bonora G. Marchetti E. Villa G. Taliani A. Castagna, M. Lichtner Selected Posters 1. Experience of acute hepatitis C and HIV co-infection A. Iodice, V. Iodice Azienda Ospedaliera Caserta, Italy 2. Differential Maturing Level of NK Cells Derived from HIV+ Patient Peripheral Blood CD34+ Cells Compared with to NK Maturing from Cord Blood Precursors F. Bozzano1,2, F. Marras3, G. Cenderello4, C. Dentone5, A. Di Biagio6, L.A. Nicolini6, C. Viscoli7, G. Bentivoglio3, F. Antonini3, C. Cantoni3, M.L. Ascierto8,9, A. Moretta1,2, L. Moretta3, A. De Maria2,6 1 Department of Experimental Medicine, University of Genoa, Italy; 2Center of Excellence for Biomedical Research, University of Genoa, Italy; 3G. Gaslini Institute, Genoa, Italy; 4Department of Infectious Diseases, Ospedali Galliera, Genoa, Italy; 5San Remo Hospital, Imperia, Italy; 6IRCCS AOU San Martino-IST Genoa, Italy; 7Clinical Infectious Diseases, IRCCS AOU San MartinoIST Genoa, Italy; 8Department of Transfusion Medicine, Clinical Center and Center of Human Immunology, National Institutes of Health, Bethesda, MD, USA; 9Department of Oncology, Johns Hopkins University, Baltimore, MD, USA 3. Distinct NK Cell Regulation in Virologically Discordant Non Progressor Patients, Addictional to EC/LTNP F. Marras1, F. Bozzano2, A. Di Biagio3, L. Nicolini3, C. Viscoli3, C. Dentone4, E. Pontali5, S. Boni6, M. Setti3,7, G. Orofino8, E. Mantia9, L. Moretta1, C. Orlandi10, A. Casabianca10, M. Magnani10, A. De Maria2,11 1 Istituto Giannina Gaslini, Genoa, Italy; 2Department of Experimental Medicine, DIMES, University of Genoa, Genoa, Italy; Department of International Medicine and Infectious Disease IRCCS A.O.U. SanMartino-IST Genoa, Italy; 4Unità di Malattie Infettive, Ospedale Sanremo, Sanremo (GE), Italy; 5Unità di Malattie Infettive, Ospedale Galliera, Genoa, Italy; 6Unità di Malattie Infettive, Ospedale Sant’Andrea, La Spezia, Italy; 7Department of Internal Medicine, University of Genoa, Genoa, Italy; 8Unità di Malattie Infettive, Ospedale Amedeo di Savoia, Turin, Italy; 9Unità di Malattie Infettive, Az. Osp. Santi A.B.C. Arrigo, Alessandria, Italy;10Department of Biomolecular Science University of Urbino "Carlo Bo", Urbino (PU), Italy; 11Center of Excellence in Biomedical Research, University of Genoa, Genoa, Italy 3 4. Proviral DNA and Inflammation during cART in Primary or Chronic Infection: ALPHA Study G. Rozera, I. Abbate, C. Pinnetti, N. Orchi, P. Pierro, P. Lorenzini, A. Amendola, V. Bordoni, A. Antinori, M.R. Capobianchi, A. Ammassari National Institute for Infectious Disease “L. Spallanzani”, Rome, Italy 5. High levels of HBsAg with low plasmatic HBV-DNA in young African refugees with HBV genotype infection: an indication for early treatment V. Malagnino1, C. Sarrecchia1, C. Cerva1, V. Svicher2, M. Pollicita2, L. Colagrossi2, M. Aragri2, R. Salpini2, A. Ricciardi1, G. MaffongelliI1, L. Dori1, C.F. Perno2, M. Andreoni1, L. Sarmati1 1 Clinic of Infectious Diseases, Policlinico Tor Vergata of Rome, Italy; 2Department of Experimental Medicine and Surgery, University of Tor Vergata, Rome, Italy 6. Bone and Vascular Diseases in HIV Infected Patients: Is There a Link? A. D’Abramo, M.A. Zingaropoli, A. Oliva, C. D’Agostino, M. Iannetta, G. d’Ettorre, M.R. Ciardi, C.M. Mastroianni, V. Vullo “Sapienza” University of Rome, Italy 7. Impact of HCV RNA on Epidemiological, Viroimmunological, Clinical and Therapeutic Basal Features in HIV/HCV Positive Subjects Enrolled in Master Cohort M. Giralda1, P. Nasta1, F. Borghi1, A. Saracino2, F. Maggiolo3, S. Digiambenedetto4, M. Di Pietro5, L. Sighinolfi6, A. Zoncada7, S. Costarelli8, F. Castelli1, G. Carosi9 and the MaSTER study group 1 University Division of Infectious and Tropical Diseases, University of Brescia, Italy; 2Infectious Diseases, Policlinico di Bari, Italy; Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo, Italy; 4Infectious Diseases, Policlinico A. Gemelli - Catholic University, Roma, Italy; 5Infectious Diseases, S.M. Annunziata Hospital, Firenze, Italy; 6Infectious Diseases, Nuovo Polo Ospedaliero di Cona, Ferrara, Italy; 7Infectious Diseases, Istituti Ospitalieri, Cremona, Italy; 8Infectious Diseases, San Gerardo Hospital, Monza, Italy; 9MISI Foundation, Italy 3 11 Selected Posters 8. Inflammatory myeloid subsets expansion in AIDS and non AIDS presenters S. Savinelli1, M. Lichtner2, C. Mascia1, R. Rossi1, R. Marocco2, E.N. Cavallari1, G. d’Ettorre1, F. Schiavone2, C.M. Mastroianni2, V. Vullo1 1 Department of Public Health and Infectious Diseases, University of Rome "Sapienza”, Italy; 2Infectious Diseases Unit, Polo Pontino, University of Rome "Sapienza", Italy 9. Analysis of innate immune response in HCV mono-infected, HCV/HIV co-infected and HIV monoinfected patients under effective ART F. Schiavone2, M. Lichtner1, C. Mascia2, S. Savinelli2, T. Tieghi1, R. Marocco1, S. Vita2, P. Zuccalà2, R. Rossi2, F. Mengoni2, C.M. Mastroianni1, V. Vullo2 1 Infectious Diseases Unit, Sapienza University, Latina, Italy; 2Public Health and Infectious Diseases, Sapienza University, Rome, Italy 10. A Web Portal for Clinical and Genotype Data Management for the Study of Hepatocellular Carcinoma R. Alfieri1, M. Santoro2, M. Gnocchi1, M. Moscatelli1, O. Carpina3, C. Vischi3, C. Pisano4, V. De Murtas4, E. Polilli5, F. P. Antonucci2, I. Maida4, P. Tarquini6, G. Garrucciu7, F. Bandiera8, D. Di Giammartino6, D. Laccabue9, A. Olivani9, V. Borghi10, T. Quirino11, I. Lenci12, G. Tisone12, M. Angelico12, C. Mussini10, G. Rizzardini13, M. Temponi3, G. Parruti5, M.S. Mura4, F. Ceccherini-Silberstein2, C.F. Perno2, L. Milanesi1 1 Istituto di Tecnologie Biomediche - CNR, Segrate (MI), Italy; 2Università degli Studi di Roma Tor Vergata, Roma, Italy; 3Flaconix, Capriano Del Colle (BS), Italy; 4Università degli Studi di Sassari, Sassari, Italy; 5ASL Pescara PO Santo Spirito, Pescara, Italy; 6Ospedale G. Mazzini di Teramo, Italy; 7Azienda Ospedaliera Universitaria di Sassari, Italy; 8Ospedale Santissima Annunziata di Sassari, Italy; 9Azienda Ospedaliera-Universitaria di Parma, Italy; 10Azienda Ospedaliero Universitaria di Modena Policlinico, Italy; 11Azienda Ospedaliera Ospedale di Busto Arsizio (VA), Italy; 12Fondazione Policlinico Tor Vergata, Roma, Italy; 13Azienda Ospedaliera e Polo Universitario Ospedale Luigi Sacco, Milano, Italy 11. Evaluation of Durability of 3 First-Line cART Regimens including Atazanavir/ritonavir, Darunavir/ritonavir and Raltegravir in Patients Enrolled in a Large Italian Cohort (MASTER) C. Torti1,3, A. Saracino2, C. Pezzoli3, C. Casari3, F. Maggiolo4, S. Digiambenedetto5, M. Di Pietro6, L. Sighinolfi7, A. Zoncada8, S. Costarelli9, N. Mazzini11, M.C. Postorino1, M. Braggion10, G. Carosi11 and the MaSTER study group 1 Unit Operation Infectious Diseases, University of Magna Grecia, Catanzaro, Italy; 2Infectious Diseases, Policlinico di Bari, Italy; Infectious Diseases, University of Brescia, Italy; 4Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo, Italy; 5Infectious Diseases, Policlinico A. Gemelli - Catholic University, Rome, Italy; 6Infectious Diseases, S.M. Annunziata Hospital, Firenze, Italy; 7Infectious Diseases, Nuovo Polo Ospedaliero di Cona, Ferrara, Italy; 8Infectious Diseases, Istituti Ospitalieri, Cremona, Italy; 9Infectious Diseases, San Gerardo Hospital, Monza, Italy; 10Foundation of Ca' Foscari University, Venice, Italy; 11MISI Foundation, Italy 3 13 General information Workshop Venue Palazzo delle Stelline Corso Magenta, 61 - 20123 Milan, Italy www.stelline.it orkshop Innovation in HIV and Viral Hepatitis Beyond viral undetectability: orkshop new frontiers and strategies Innovation in HIV and Viral Hepatitis Beyond viral undetectability: new frontiers and strategies CME Provider and Organizing Secretariat Effetti srl Milan, Italy January 26-27, 2015 Via Gallarate, 106 - 20151 Milan, Italy Phone +39 02 3343281 - Fax +39 02 38002105 Mail: [email protected] Official language English. No simultaneous translation provided. CME accreditation The Workshop has obtained 9 CME credits (ID number 150-112131) from Italian Health Ministry for the following professionals: Medical Doctor, Biologist, Territory and Hospital Pharmacist, Nurse, Medical Laboratory Technician and Psychologist. Medical specialties include: Infectious and Tropical Diseases, Hygiene, Epidemiology and Public Health, Microbiology and Virology, Allergology and Clinical Immunology, Internal Medicine and Gastroenterology. Credits will be given only to participants attending 100% of the teaching event and answering correctly to at least 75% of the final assessment questionnaire. Participants are also required to wear the identification badge during working sessions, to provide their signature for attendance tracking purposes and to complete the satisfaction questionnaire. Poster session Authors may post up their posters subject to registration. The selected posters should be affixed in the foyer outside Sala Volta (1st floor), one hour before the beginning of the Workshop and taken away at the end of the scientific works. Posters should be prepared in English. During poster discussion, authors are kindly requested to remain close to their own poster for answering questions. Cyber point A Cyber point is available at exhibition area in the foyer outside Sala Volta (1st floor). Slide center A slide center will be available to speakers, with computers, CD writer, printer and technical support. Only Powerpoint slide presentations will be accepted. If a special equipment is needed, it should be communicated in advance to the Organizing Secretariat. Slides must be submitted 2 hours before the scheduled presentation. Technical equipment Congress room is suitable for Powerpoint presentations and equipped with computers and overhead projectors. Speakers may not use their own computers for their presentations. Exhibition area A technical-pharmaceutical and scientific publishing exhibition area will be open from 11:00 a.m. on Monday January 26th to 01:30 p.m. on Tuesday January 27th. Web repository Abstracts (oral and poster) and slide presentations of authors who provide their consent will be published on Workshop web site (www.innovation2015.it) at the end of the event. www.innovation2015.it The Scientific Coordinators, the Scientific Secretariat and the CME Provider wish to thank for support given in the form of unrestricted educational grants the following Companies: PLATINUM SPONSOR GOLD SPONSOR OTHER SPONSORS Supported by Gilead Sciences Europe Ltd who provided funding. Gilead Sciences Europe Ltd has had no input into the content of the materials and presentations.
© Copyright 2019 ExploreDoc